We are proud to announce that Guillaume Canaud, head of the Translational Medicine and Targeted Therapies team and physician at the Necker Enfants Malades Hospital, is among the 15 recipients of the latest round of Chairs of Excellence in Biology/Health awarded as part of the France 2030 initiative, an ambitious program aimed at enhancing the attractiveness of French biomedical research.

His project, KRASY, tackles a major clinical challenge: arteriovenous malformations (AVMs) of somatic origin, driven by activating mutations in the KRAS gene, particularly in the brain. These anomalies remain poorly understood and currently have no approved treatments. However, because KRAS mutations are also common in cancer, this opens up opportunities to repurpose therapies initially developed for oncology.

The project aims to develop new preclinical models, decipher the mechanisms underlying KRAS-induced AVMs, and identify novel targeted therapies, with the ultimate goal of offering precision medicine to affected patients.

This funding will support the program over a five-year period.

Meet the other awardees: https://www.enseignementsup-recherche.gouv.fr/fr/france-2030-attractivite-de-la-recherche-francaise-15-nouveaux-chercheurs-et-chercheuses-distingues-99537